Evaluation of imidazo[2,1-b]thiazole-based anticancer agents in one decade (2011-2020): Current status and future prospects

Bioorg Med Chem. 2021 Jan 1:29:115897. doi: 10.1016/j.bmc.2020.115897. Epub 2020 Nov 28.

Abstract

Several reports have highlighted imidazo[2,1-b]thiazole derivatives as potential antiproliferative agents. They act through kinase inhibition, tubulin inhibition, and other molecular mechanisms of action. In the current article, we reviewed the imidazo[2,1-b]thiazole-based compounds that were reported as anticancer agents. Their biological characteristics as well as structure-activity relationship (SAR) have been reviewed and evaluated. Our main focus was on the reports published in the literature from 2011 to 2020.

Keywords: Anticancer; Antiproliferative; Imidazo[2,1-b]thiazole; Imidazothiazole; Kinase inhibitor; Tubulin.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Drug Screening Assays, Antitumor
  • ErbB Receptors / antagonists & inhibitors
  • Humans
  • Imidazoles / chemistry*
  • Models, Molecular
  • Protein Binding
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / pharmacology
  • Ribosomal Protein S6 Kinases, 90-kDa / antagonists & inhibitors
  • Signal Transduction
  • Structure-Activity Relationship
  • Thiazoles / chemistry*
  • Thiazoles / pharmacology
  • Tubulin / metabolism

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Protein Kinase Inhibitors
  • Thiazoles
  • Tubulin
  • ErbB Receptors
  • Ribosomal Protein S6 Kinases, 90-kDa
  • ribosomal protein S6 kinase, 90kDa, polypeptide 3